Invention Grant
- Patent Title: Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
-
Application No.: US15539401Application Date: 2015-12-23
-
Publication No.: US10738011B2Publication Date: 2020-08-11
- Inventor: Cecilia M. Bastos , Benito Munoz , Bradley Tait
- Applicant: Proteostasis Therapeutics, Inc.
- Applicant Address: US MA Boston
- Assignee: Proteostasis Therapeutics, Inc.
- Current Assignee: Proteostasis Therapeutics, Inc.
- Current Assignee Address: US MA Boston
- Agency: Goodwin Procter LLP
- International Application: PCT/US2015/000211 WO 20151223
- International Announcement: WO2016/105484 WO 20160630
- Main IPC: C07D231/14
- IPC: C07D231/14 ; C07D249/06 ; C07D413/12 ; C07D403/12 ; C07D405/12 ; A61P11/00 ; A61K31/415 ; A61K31/4155 ; A61K31/4178 ; A61K31/5377 ; A61K45/06 ; G01N33/68
Abstract:
The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IVa), (Va), (IV), or (V) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Public/Granted literature
Information query
